Millendo Therapeutics, Inc.
MLND · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | – | $3 | $6 | $1 |
| - Cash | $30 | $38 | $62 | $73 |
| + Debt | $8 | $3 | $5 | $1 |
| Enterprise Value | – | -$33 | -$52 | -$72 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | -$35 | -$45 | -$27 |
| % Margin | – | – | – | – |
| Net Income | -$42 | -$36 | -$45 | -$27 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.5 | -28.95 | -48.77 | -263.65 |
| % Growth | 94.8% | 40.6% | 81.5% | – |
| Operating Cash Flow | $0 | -$30 | -$41 | -$24 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$30 | -$42 | -$24 |